Pasithea Therapeutics Corp.

NASDAQ: KTTA · Healthcare · Biotechnology

PublicHQ Miami Beach, FL · Miami-DadeCIK 0001841330Reports USD

#941 of 1,422 Healthcare companies by revenuetop-decile growth

EA Score

32D

FH 45DQ 15GM —SS 27

v0.1 · 55/100 weight · provisional

↑ revenue growth (YoY), balance-sheet leverage · ↓ disclosure history, operating margin

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$20.4M

Employees

as of 2026-08-24

Market cap

$18.0M

as of 2026-08-24

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$486.6k$486.6k2022

Net income-$20.4M-$20.4M2025

Operating income-$20.9M-$20.9M2025

Total assets$60.2M$60.2M2025

Liabilities$5.0M$5.0M2025

Equity$55.2M$55.2M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Pasithea Therapeutics Corp.’s revenue?

Pasithea Therapeutics Corp. booked $486.6k in FY2022 revenue, growing 3130% year over year — faster than 98% of Healthcare companies we track, at a -4198.4% net margin.

Peers · Healthcare

Zenith Capital Corp.——Imunon, Inc.39D Bioelectronics Corporation——Positron Corporation28D Speedus Corp.——Mangoceuticals, Inc.30D

Neighbors

Miami-Dade →

Palantir Technologies Inc.$4.5B78B+Royal Caribbean Cruises Ltd.$17.9B80B+Carnival Corporation & plc$26.6B72B MasTec, Inc.$14.3B77B+Lennar Corporation$34.2B74B Watsco, Inc.$7.2B73B

Key facts

CEOTiago Reis Marques

SectorHealthcare

IndustryBiotechnology

HeadquartersMiami Beach, FL

ExchangeNASDAQ: KTTA

Employees5

IPO date2021-09-15

Latest filings

8-K2026-08-21 10-Q2026-08-14 DEF 14A2026-08-07 10-Q2026-05-15 8-K2026-05-04 10-K2026-03-30 8-K2026-02-20 8-K2026-01-28

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.